Search research articles
Contact Us
Filters
Showing results (701-710 of 718) with videos related to
Page
of 72
Sort By:
Viruses
|
January 8, 2025
Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice
Mayara Mattos, Carolina Q Sacramento, André C Ferreira, et al.
Brain, Behavior, & Immunity - Health
|
July 18, 2024
Changes in neuroinflammatory biomarkers correlate with disease severity and neuroimaging alterations in patients with COVID-19 neurological complications
Fernanda G Q Barros-Aragão, Talita P Pinto, Victor C Carregari, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitors
Leon M Smith, Michael J Orwat, Zilun Hu, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
Charles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Frontiers in Immunology
|
August 3, 2023
Transcriptomic profiles of multiple organ dysfunction syndrome phenotypes in pediatric critical influenza
Tanya Novak, Jeremy Chase Crawford, Georg Hahn, et al.
Medicine
|
April 19, 2018
Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
Gareth I Owen, Mauricio P Pinto, Ignacio N Retamal, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 10, 2005
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency
A Arasappan, F G Njoroge, T-Y Chan, et al.
Page
of 72
Search research articles
Search
Showing results (701-710 of 718) with videos related to
Sort By:
Page
of 72
Viruses
|
January 8, 2025
Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice
Mayara Mattos, Carolina Q Sacramento, André C Ferreira, et al.
Brain, Behavior, & Immunity - Health
|
July 18, 2024
Changes in neuroinflammatory biomarkers correlate with disease severity and neuroimaging alterations in patients with COVID-19 neurological complications
Fernanda G Q Barros-Aragão, Talita P Pinto, Victor C Carregari, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitors
Leon M Smith, Michael J Orwat, Zilun Hu, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability
Charles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry
|
October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)
Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Frontiers in Immunology
|
August 3, 2023
Transcriptomic profiles of multiple organ dysfunction syndrome phenotypes in pediatric critical influenza
Tanya Novak, Jeremy Chase Crawford, Georg Hahn, et al.
Medicine
|
April 19, 2018
Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients
Gareth I Owen, Mauricio P Pinto, Ignacio N Retamal, et al.
Journal of Medicinal Chemistry
|
September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy
Andrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry
|
December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups
James R Corte, Donald J P Pinto, Tianan Fang, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 10, 2005
Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency
A Arasappan, F G Njoroge, T-Y Chan, et al.
Page
of 72